P/B
—
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
$44.1M
Market Cap • 10/9/2026
2021
(5 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
44,1M
EV
61,3M
EV/Revenue
0
EV/EBITDA
-2,9
EV/EBIT
-2,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-22,9%
Total Yield
-22,9%
Payout
0%
Retained Earnings
-150,9M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
31,2%
% Goodwill
0%
ROE
235,3%
ROIC
—
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
0,3
Quick Ratio
0,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!